Capricor: Maintaining Hold Rating In Light Of Deramiocel Complete Response Letter

Terry Chrisomalis
Investing Group Leader

Summary

  • I maintain a Hold rating on Capricor Therapeutics, Inc., despite the FDA's Complete Response Letter for deramiocel due to efficacy concerns because there is still a possible pathway for approval.
  • Capricor still has a viable path with the ongoing phase 3 HOPE-3 trial data expected in Q3 2025 and an upcoming FDA Type A meeting.
  • CAPR is financially stable, with cash reserves sufficient to fund operations into 2027, reducing immediate dilution risk.
  • The global Duchenne Muscular Dystrophy market in the 7 major markets is expected to reach $5.2 billion by 2033; 95% of DMD patients by the age of 20 develop cardiomyopathy.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Lab, science and people on tablet for meeting with medical research, discussion and teamwork. Healthcare, biotechnology and man and woman with equipment for sample, experiment and cure for vaccine

Jacob Wackerhausen

The last time I wrote about Capricor Therapeutics, Inc. (NASDAQ:CAPR), it was in a Seeking Alpha article entitled "Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement." With respect

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.53K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About CAPR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CAPR

Related Stocks

SymbolLast Price% Chg
CAPR
--
Compare

Trending Analysis

Trending News